Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3877 | TD-1473 [Tablet B] Wiki | 0.33 |
| drug844 | Cannabis, Medical Wiki | 0.33 |
| drug3876 | TD-1473 [Tablet A] Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007410 | Intestinal Diseases NIH | 0.67 |
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.33 |
| D005879 | Tourette Syndrome NIH | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001714 | Bipolar Disorder NIH | 0.24 |
| D003092 | Colitis NIH | 0.20 |
| D003093 | Colitis, Ulcerative NIH | 0.20 |
| D003424 | Crohn Disease NIH | 0.20 |
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.19 |
| D012640 | Seizures NIH | 0.19 |
| D016472 | Motor Neuron Disease NIH | 0.19 |
| D000755 | Anemia, Sickle Cell NIH | 0.17 |
| D005356 | Fibromyalgia NIH | 0.15 |
| D001927 | Brain Diseases NIH | 0.15 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.11 |
| D010300 | Parkinsonian NIH | 0.11 |
| D001930 | Brain Injuries, NIH | 0.09 |
| D059350 | Chronic Pain NIH | 0.09 |
| D009103 | Multiple Sclerosis NIH | 0.08 |
| D012598 | Scoliosi NIH | 0.08 |
| D040921 | Stress Disorders, Traumatic NIH | 0.06 |
| D014947 | Wounds and Injuries NIH | 0.06 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.06 |
| D004194 | Disease NIH | 0.05 |
| D013577 | Syndrome NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002037 | Inflammation of the large intestine HPO | 1.00 |
| HP:0002242 | Abnormal intestine morphology HPO | 0.67 |
| HP:0100754 | Mania HPO | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002583 | Colitis HPO | 0.20 |
| HP:0100279 | Ulcerative colitis HPO | 0.20 |
| HP:0100280 | Crohn's disease HPO | 0.20 |
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.19 |
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.19 |
| HP:0001250 | Seizure HPO | 0.17 |
| HP:0001298 | Encephalopathy HPO | 0.15 |
| HP:0012532 | Chronic pain HPO | 0.09 |
Navigate: Correlations HPO
There are 9 clinical trials
Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications. Sometimes, concerns about transfer of drugs to infants via breast milk lead the mothers to either avoid breastfeeding or stop their medication. Inflammatory Bowel Disease (IBD) is a chronic condition that is marked by an abnormal response of the body's immune system, and high levels of certain proteins that cause inflammation (Cytokines like Tumor Necrosis Factor-alpha or TNFα). A group of drugs called "biologics" target and stop these proteins from causing inflammation, and have been successfully used to treat this condition. Inflammatory proteins may be present in breast milk of healthy women in variable levels, and may play a role in development of infant's brain and immune system. This study is being conducted to investigate: - Concentration of some of the inflammatory proteins in breast milk of mothers with IBD and healthy controls - Interaction between these proteins and biologics in breast milk of women with IBD - Potential role of these proteins (and their interaction with biologics) on development of infant learning and memory function It has been presumed that concentrations of TNFα and some other cytokines are higher in breast milk of women with IBD, and the biologics can normalize these high levels. Due to precautions for COVID-19, the study now consists of only two mandatory study visits and two optional study visits. The mandatory visits include two home visits in the first 4 months postpartum to complete a participant questionnaire and collect a small sample of breast milk at each visit. The optional study visits consist of two visits at the Hospital for Sick Children for evaluation of learning and memory function of the infant at the ages of 12 and 18 months. Additionally, mothers will be required to complete for their infant subscales of The Ages and Stages Questionnaires®, Third Edition (ASQ®-3) either in person or over the telephone at the ages of 12 months and 18 months.
Description: Multiplex assay will be used to measure TNFα and downstream chemokines including CCL2, CCL4, CCL7, CXCL10 in breast milk of two groups of participants (women with IBD and healthy controls). (The unit of measurement is the same for all these cytokines)
Measure: Levels of TNFα and its downstream chemokines (CCL2, CCL4, CCL7, and CXCL10) in breast milk of women with IBD and healthy controls by Multiplex assay Time: 4 yearsDescription: ELISA assay will be used to measure total and free drug levels (bound and unbound to TNFα) in breast milk of lactating women with IBD. (The unit of measurement is the same for infliximab and adalimumab).
Measure: Milk concentration of TNFα inhibitors (infliximab, adalimumab) at different time-points between two doses of medication, in lactating women with IBD by ELISA assay Time: 4 yearsDescription: The infants of women with IBD and healthy controls will be examined for cognitive development using Bayley-III
Measure: Scores on cognitive subset of Bayley Scales of Infant and Toddler development- Third Version (Bayley-III) in infants of healthy controls and women with IBD Time: 4 yearsDescription: Infants of healthy controls and women with IBD will be examined for communication and problem-solving development using the ASQ®-3. This supplementary measure is intended to provide additional data as an alternative to Bayley test under unprecedented circumstances which preclude participants to complete Bayley test at the Hospital for Sick Children
Measure: Scores on the "Problem-solving" and "Communication" subscales of The Ages and Stages Questionnaire (ASQ®-3) in infants of healthy controls and women with IBD Time: 4 yearsDescription: An estimation of the population distribution of anti-TNFα antibodies (infliximab and adalimumab) in breast milk of women with IBD will be made, using population pharmacokinetic modelling
Measure: Simulated/predicted profiles of TNFα inhibitors (infliximab, adalimumab) in breast milk in a large population of lactating women with IBD by population pharmacokinetic modelling Time: 4 yearsThis will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsMulticenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 yearDescription: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. weight (Kg) height (m) ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. ACCOMMODATION HOUSING AREA number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearThe rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.
Description: Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period
Measure: Patient's perception of COVID-19 and medical use patterns Time: 1dayDescription: Exacerbation of symptoms in patients with IBD during the pandemic period
Measure: Exacerbation of symptoms Time: 1dayTo find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease
Whether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes
Description: The need for in-hospital colectomy or rescue therapy
Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy Time: 3 monthsDescription: Duration and type/route of steroid use
Measure: 2.1: Duration and type/route of steroid use Time: 3 monthsDescription: 30 day colectomy free survival rates
Measure: 2.2: 30 day colectomy free survival rates Time: 3 monthsDescription: Covid-19 infection rates
Measure: 2.3: Covid-19 infection rates Time: 3 monthsDescription: Rate of Rescue therapy use
Measure: 2.4: Rate of Rescue therapy use Time: 3 monthsDescription: Duration of hospital stay
Measure: 2.5: Duration of hospital stay Time: 3 monthsDescription: Admission severity scoring
Measure: 2.6: Admission severity scoring Time: 3 monthsDescription: Readmission rates
Measure: 2.7: Readmission rates Time: 3 monthsThe coronavirus pandemic has changed healthcare dramatically in a short time. Individuals with chronic illnesses and services for them have had to adapt and change to deal with requirements for shielding and social isolation to reduce infection risk and management of medication investigation and ongoing review. It is increasingly recognised that the pandemic and the changes to daily life will have had a series of impacts on patients and health care services, including impacts on patients psychological well-being and the opportunity to seek medical care for non-CoViD illness. Psychological symptoms such as depression, anxiety and hopelessness is well described in adults and young people with inflammatory bowel disease. Quarantine has also been associated with these psychological symptoms and also post-traumatic stress. It is important to identify the extent of and factors that influence negative psychological consequences of isolation in patients with inflammatory bowel disease. This study will aim to assess what impact the isolation of patients during social isolation had in terms of psychological well-being - and what are the factors affecting this impact, particularly in younger and old age groups.
Description: Psychological morbidity will be assessed through the 4 questionnaires
Measure: What impact has the isolation of patients during social isolation had in terms of psychological morbidity? Time: Changes in psychological morbidity at 12 monthsDescription: psychological morbidity will be assessed via comparison of questionnaires from affiliated study against the time points of this study
Measure: Have levels of psychological morbidity in young people changed from levels prior to the CoViD pandemic? Time: Changes in psychological morbidity at 12 monthsMost of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may increase patients' risk of infection, in particular viral infection. Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and mortality, may have a negative impact on IBD patients' clinical course. Identifying an increased risk in this particular patients' population as well as the risk/protective factors is of outstanding importance, in order to adapt their treatment and surveillance. As a consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by biological testing or suspected due to record of potential clinical symptoms of COVID-19 infection) in this patients' cohort (principal objective), (ii) to identify risk or protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of patients in case of suspected or confirmed COVID-19. The results of this study may be important to adjust our surveillance and therapeutic strategy in these patients, in particular if high virus circulation will occur in the future.
This is a Phase 1, 2-part, open-label study. Part A will be a formulation bridging and food effect study in healthy adult subjects. Part B will be an assessment of pharmacokinetics (PK) in healthy adult Chinese subjects.
Description: Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) of TD-1473 in Plasma
Measure: AUC0-t Time: Predose and at prespecified time points up to 5 days after dosing on Day 1 of each periodDescription: Area under the concentration-time curve, from time 0 extrapolated to infinity (AUC0-inf) of TD-1473 in Plasma
Measure: AUC0-inf Time: Predose and at prespecified time points up to 5 days after dosing on Day 1 of each periodDescription: Maximum observed concentration (Cmax) of TD-1473 in Plasma
Measure: Cmax Time: Predose and at prespecified time points up to 5 days after dosing on Day 1 of each periodDescription: Number and severity of treatment emergent adverse events.
Measure: Adverse events Time: Day 1 through Day 7 of each periodAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports